| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Mallinckrodt plc (STU: MCD)
MCD Technical Analysis
5
| As on 21st Jun 2022 MCD STOCK Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 107.36 & Strong Sell for SHORT-TERM with Stoploss of 0.29 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MCDSTOCK Price
| Open | 0.01 | Change | Price | % |
| High | 0.01 | 1 Day | 0.00 | 0.00 |
| Low | 0.01 | 1 Week | -0.02 | -66.67 |
| Close | 0.01 | 1 Month | -0.05 | -83.33 |
| Volume | 5000 | 1 Year | -0.15 | -93.75 |
| 52 Week High 5041.00 | 52 Week Low 0.01 | ||||
STU Germany Most Active Stocks
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TINC | 0.01 | -1.50% |
| PGF | 19.13 | -90.20% |
| PGF | 19.13 | -90.20% |
| DMJ | 0.17 | 6.25% |
| DMJ | 0.17 | 6.25% |
STU Germany Top Gainers Stocks
STU Germany Top Losers Stocks
| MCD Daily Charts |
MCD Intraday Charts |
Whats New @ Bazaartrend |
MCD Free Analysis |
|
|
MCD Important Levels Intraday
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
MCD Forecast May 2024
| 4th UP Forecast | 0.82 |
| 3rd UP Forecast | 0.56 |
| 2nd UP Forecast | 0.4 |
| 1st UP Forecast | 0.24 |
| 1st DOWN Forecast | -0.22 |
| 2nd DOWN Forecast | -0.38 |
| 3rd DOWN Forecast | -0.54 |
| 4th DOWN Forecast | -0.8 |
MCD Weekly Forecast
| 4th UP Forecast | 0.14 |
| 3rd UP Forecast | 0.10 |
| 2nd UP Forecast | 0.07 |
| 1st UP Forecast | 0.05 |
| 1st DOWN Forecast | -0.03 |
| 2nd DOWN Forecast | -0.05 |
| 3rd DOWN Forecast | -0.08 |
| 4th DOWN Forecast | -0.12 |
MCD Forecast2024
| 4th UP Forecast | 9714 |
| 3rd UP Forecast | 6598.67 |
| 2nd UP Forecast | 4673.01 |
| 1st UP Forecast | 2747.35 |
| 1st DOWN Forecast | -2747.33 |
| 2nd DOWN Forecast | -4672.99 |
| 3rd DOWN Forecast | -6598.65 |
| 4th DOWN Forecast | -9713.98 |
Mallinckrodt plc ( STU Germany Symbol : MCD )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
MCD Business Profile
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an acetaminophen injection; Therakos photopheresis, an immunotherapy treatment platform; and Amitiza for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. In addition, it offers specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc for the development and commercialization of ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Address: College Business & Technology Park, Dublin, Ireland, 15
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service